Fulgent Genetics Increases Full-Year Guidance by Nearly 30 Percent

Nov 23, 2020

|

NEW YORK – Fulgent Genetics said on Monday that it has increased its full-year 2020 revenue estimate by nearly 30 percent as a result of growing demand for its COVID-19 testing solutions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Featured White Papers

The Great Unknown of DNA Sequencing Variants: What You Need to Know

Compatibility of Liquid Biopsy Assays on Multiple Sequencing Platforms

The Challenges of Sequencing HBA1/2 Genes for Alpha-Thalassemia Research: A GenomeWeb eCase Study Transcript

Decoding Carrier Screening

Feb

24

Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.

Menu

Fulgent Genetics Increases Full-Year Guidance by Nearly 30 Percent

To read the full story....

Breaking News

Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Bionano Genomics to Raise $200M in Public Stock Offering

CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

Interpace Bio Q3 Revenues Rise 6 Percent

Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

Predictive Oncology Prices $2.2M Direct Offering